BioTech/Drugs - Cambridge, MA, US
Fractal Therapeutics is a model-based drug discovery and development company, focused on discovery, translation and early clinical development for assets in Oncology and Infectious Disease.Our team consists of seasoned biotech and pharma executives with extensive experience in discovery, IND-enabling and early clinical pharmacology. We specialize in advancing molecules in a rapid and capital-efficient manner, using an interdisciplinary approach that couples PK/PD modeling tightly with in vivo and clinical pharmacology. Taking a broader engineering approach, we frame questions in preclinical and early-clinical development in terms of modeling and informatics analyses that can often be addressed with existing experimental data, allowing more progress for each unit of experimental effort.We engage (on a target and modality-exclusive basis) with early-stage partners on their programs, using our approaches to provide robust model-based answers to critical-path questions on the road to new asset creation and development. We are also applying our interdisciplinary platforms to efficiently build a pipeline of novel investigational agents, which we are looking to partner for early clinical development. At present, our internal pipeline is heavily focused on COVID-19, and we are actively involved in contributing to the scientific and biomedical response to the pandemic. Our work is focused on leveraging epidemiological and PK/PD modeling approaches to define the strategy for interventions aimed at SARS-CoV-2. We share design principles uncovered by our modeling in a precompetitive manner with the community, while employing them in the discovery and development of candidate therapeutics and prophylactics for our own pipeline.
reCAPTCHA
Outlook
Apache
Google Tag Manager
Bootstrap Framework
Mobile Friendly